Haisco Pharmaceutical   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Liaoning China (2005)
Status: No NME R&D (2005)

Organization Overview

First Clinical Trial
2014
NCT04033939
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Haisco Pharmaceutical(Australia) Pty Ltd. | Haisco Pharmaceutical Group Co., Ltd. | Haisco-USA Pharmaceuticals, Inc. | Sichuan Haisco Pharmaceutical Group Co., Ltd | Sichuan Haisco Pharmaceutical Group Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Agnosia (Phase 2)

Chemical and Drug Induced Liver Injury (Phase 4)

Chronic Pain (Phase 1)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Diabetic Neuropathies (Phase 3)

Liver Diseases (Phase 1)

Neuralgia (Phase 3)

Pain, Postoperative (Phase 1)

Prostatic Neoplasms (Phase 3)

Pruritus (Phase 2)

Renal Insufficiency (Phase 1)

Renal Insufficiency, Chronic (Phase 1)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 81
  • # of Trial APIs: 32